Pfizer called a buy at Jefferies after guidance cut: 5 big analyst picks
Investing.com — Here is your Pro Recap of the biggest analyst picks you may have missed today: several Buy initiations at Instacart, and upgrades at) shares kicked higher Monday after analysts issued glowing notes after the healthcare giant lowered its revenue and earnings forecasts for the year, given the decline in demand for its COVID-19 treatment, Paxlovid.
Pfizer said it now sees adjusted EPS at $1.55, down from the prior guidance of $3.35. Full-year revenue is now seen at $59.5 billion, down from the previous $68.5 billion. But some analysts, including those at Jefferies, responded favorably to the revised guidance. Jefferies notably shifted its rating from Hold to Buy with a price target of $39.00 , driven by several key factors: the guidance adjustment is predominantly influenced by Paxlovid, Comirnaty's performance is exceeding buy-side expectations, cost reductions totaling $3.
The company is set to report its Q3/23 earnings on Nov 1. Street estimates stand at for EPS and $2.98 billion for revenues.Citi, for instance, began its analysis of the company with a Buy rating, setting a price target of $34.00. Considering the 12% penetration of Online Grocery , coupled with Instacart’s strong tech partnerships with many leading U.S.
{username} Just Now Share Follow this postUnfollow this post Save Saved. See Saved Items . This comment has already been saved in your Saved Items Author's response{commentContent} Reply 00 Report {username} Just NowAuthor's response Share Follow this postUnfollow this post Save Saved. See Saved Items .
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Pfizer called a buy at Jefferies after guidance cut: 5 big analyst picksPfizer called a buy at Jefferies after guidance cut: 5 big analyst picks
Baca lebih lajut »
Pfizer gets upgrade at Jefferies, which says there's a buying opportunity in the pharma giant's stockJefferies recommends maintaining a long-term outlook on this key pharmaceutical stock.
Baca lebih lajut »
Pfizer, BioNTech shares fall on lower COVID product sales forecastShares of Pfizer (PFE.N) and German partner BioNTech (22UAy.DE) fell on Monday after the U.S. drugmaker slashed the sales forecast for its COVID vaccine and therapy last week, and some analysts said the reduction was bigger than expectations.
Baca lebih lajut »
Pfizer slumps after slashing full-year profit forecast on tumbling Covid salesPfizer said slumping demand for its Comirnaty covid vaccine and its Paxlovid antiviral treatment will mean sharply lower revenues for the full year.
Baca lebih lajut »
Vaccine Stocks—Including Pfizer, Moderna, BioNTech And Novavax—Slide Amid Plummeting DemandI am a senior reporter for the Forbes breaking news team, covering health and science from the London office. Previously I worked as a reporter for a trade publication covering big data and law and as a freelance journalist and policy analyst covering science, tech and health.
Baca lebih lajut »
Stocks making the biggest moves premarket: Pfizer, Lululemon, Manchester United, Rite Aid and moreThese are the stocks posting the largest moves in premarket trading.
Baca lebih lajut »